Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 6th Board of Directors 18th Meeting Resolution Announcement
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
The 6th Board of Directors' 18th Meeting of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as the "Company") was held on April 17, 2026, at 2:30 PM in the Company's meeting room, both on-site and via communication. The meeting notice was sent via email on April 7, 2026. Nine directors were expected to attend, and nine directors actually attended. Among them, Ye Chenghai, Chen Xiyu, and Chen Youhai attended the meeting via communication. The number of attending directors met the legal quorum. Some senior management personnel attended the meeting as non-voting attendees. The meeting was presided over by Mr. Ye Yuxiang, Chairman of the Company. The convening of this meeting complied with laws and regulations and the Company's Articles of Association.
The attending directors deliberated and formed the following resolutions:
I. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 General Manager's Work Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." was deliberated and approved.
The General Manager reported on the Company's operational performance in 2025 and presented future development plans. The Board of Directors approved this report.
II. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Board of Directors' Work Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." was deliberated and approved.
This report is subject to review by the Company's 2025 Annual Shareholders' Meeting.
The current independent directors Zhu Houjia, and former independent directors Liu Laiping and Wang Xuegong, respectively submitted their "2025 Independent Director Performance Reports" to the Board of Directors, and will present their performance at the Company's 2025 Annual Shareholders' Meeting. (The content of the "2025 Board of Directors' Work Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." can be found in the "Third Section, Management Discussion and Analysis" of the Company's "2025 Annual Report," and the "2025 Independent Director Performance Report" can be found on the information disclosure media: Juchao Information Network www.cninfo.com.cn.)
III. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Annual Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." and its summary were deliberated and approved.
This proposal was reviewed and approved by the Board of Directors' Audit Committee. The Board of Directors approved the aforementioned proposal.
This report and its summary are subject to review by the Company's 2025 Annual Shareholders' Meeting. (The "Summary of the 2025 Annual Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." can be found on the information disclosure media: "China Securities Journal," "Securities Times," and Juchao Information Network www.cninfo.com.cn; the "2025 Annual Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd.," the "Summary Table of Non-operating Fund Occupation and Other Related Party Transactions in 2025," the "Audit Report of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." by Daixin Certified Public Accountants (Special General Partnership), and the "Special Audit Report on the Summary Table of Non-operating Fund Occupation and Other Related Party Transactions" can be found on the information disclosure media: Juchao Information Network www.cninfo.com.cn.)
IV. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Profit Distribution Plan of Shenzhen Mindray Bio-Medical Electronics Co., Ltd." was deliberated and approved.
Considering the Company's profitability prospects, asset status, industry conditions, and market environment, the 2025 profit distribution plan is proposed as follows:
Based on the total share capital of 1,114,816,535 shares as of December 31, 2025, a cash dividend of RMB 5.50 (tax inclusive) per 10 shares will be distributed to all shareholders, totaling RMB 613,149,094.25. The remaining undistributed profits will be carried forward to subsequent years.